首页> 外文期刊>The Tokai Journal of Experimental and Clinical Medicine >Successful Treatment of Renal Cell Carcinoma With Mediastinal Lymph Node Metastasis by Interleukin-2: A case report
【24h】

Successful Treatment of Renal Cell Carcinoma With Mediastinal Lymph Node Metastasis by Interleukin-2: A case report

机译:白细胞介素2成功治疗纵隔淋巴结转移的肾细胞癌1例

获取原文
获取原文并翻译 | 示例
       

摘要

A 57-year-old woman presented to our hospital with macrohematuria. Renal cell carcinoma (RCC) of the left kidney with bilateral pulmonary and mediastinal lymph node me-tastases was diagnosed. Radical nephrectomy was performed. Pathological examination confirmed the diagnosis of RCC (pT2pN0M1), so immunotherapy was performed using interleukin-2 (IL-2). The mediastinal lymph node metastases disappeared completely after 5 months of immunotherapy. Investigation of immunological parameters showed an increase of CD8-positive T cells (CD8) and a decrease of CD14-positive cells (CD14), leading to a marked increase of the CD8/CD14 ratio. Although her pulmonary metastases are unchanged, the mediastinal metastases still show complete remission at 14 months postoperatively. The CD8/CD14 ratio may have potential as a new marker for monitoring the response of RCC to immunotherapy and selecting suitable patients for such therapy.
机译:一名57岁的女性因血尿过多而到我们医院就诊。诊断出左肾有双侧肺和纵隔淋巴结转移的肾细胞癌(RCC)。进行了根治性肾切除术。病理检查证实了RCC(pT2pN0M1)的诊断,因此使用白介素2(IL-2)进行了免疫治疗。免疫治疗5个月后,纵隔淋巴结转移完全消失。免疫学参数研究显示,CD8阳性T细胞(CD8)增加,而CD14阳性细胞(CD14)减少,导致CD8 / CD14比值明显增加。尽管她的肺转移没有改变,但纵隔转移在术后14个月仍显示完全缓解。 CD8 / CD14比率可能具有潜在的潜力,可用于监测RCC对免疫疗法的反应并选择合适的患者进行此类疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号